GridAI Technologies Corp
Follow $GRDX
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $GRDX by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredsnapshot unavailable for GRDX. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is GRDX moving today?
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
GRDX overview
Related filings and maps
Congress activity in GRDX
No receipt-qualified filings found.
GRDX contract awards, year to date.
Public federal awards linked to this ticker.
GRDX lobbying filings, year to date.
Registered lobbying filings matched to GridAI Technologies Corp.